131 related articles for article (PubMed ID: 21470623)
1. Mitoxantrone-iron oxide biodistribution in blood, tumor, spleen, and liver--magnetic nanoparticles in cancer treatment.
Krukemeyer MG; Krenn V; Jakobs M; Wagner W
J Surg Res; 2012 Jun; 175(1):35-43. PubMed ID: 21470623
[TBL] [Abstract][Full Text] [Related]
2. Magnetic drug targeting in a rhabdomyosarcoma rat model using magnetite-dextran composite nanoparticle-bound mitoxantrone and 0.6 tesla extracorporeal magnets - sarcoma treatment in progress.
Krukemeyer MG; Krenn V; Jakobs M; Wagner W
J Drug Target; 2012 Feb; 20(2):185-93. PubMed ID: 22044194
[TBL] [Abstract][Full Text] [Related]
3. Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment.
Alexiou C; Jurgons R; Schmid RJ; Bergemann C; Henke J; Erhardt W; Huenges E; Parak F
J Drug Target; 2003 Apr; 11(3):139-49. PubMed ID: 13129824
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetics, tissue distribution and magnetic resonance's response characterstics of folic acid-O-carboxymethyl chitosan ultrasmall superparamagnetic iron oxide nanoparticles in mice and rats].
Gao WH; Liu ST; Fan CX; Qi LY; Chen ZL
Yao Xue Xue Bao; 2011 Jul; 46(7):845-51. PubMed ID: 22010356
[TBL] [Abstract][Full Text] [Related]
5. Locoregional cancer treatment with magnetic drug targeting.
Alexiou C; Arnold W; Klein RJ; Parak FG; Hulin P; Bergemann C; Erhardt W; Wagenpfeil S; Lübbe AS
Cancer Res; 2000 Dec; 60(23):6641-8. PubMed ID: 11118047
[TBL] [Abstract][Full Text] [Related]
6. Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice.
Reszka R; Beck P; Fichtner I; Hentschel M; Richter J; Kreuter J
J Pharmacol Exp Ther; 1997 Jan; 280(1):232-7. PubMed ID: 8996201
[TBL] [Abstract][Full Text] [Related]
7. Real-time cell analysis of human cancer cell lines after chemotherapy with functionalized magnetic nanoparticles.
Dürr S; Lyer S; Mann J; Janko C; Tietze R; Schreiber E; Herrmann M; Alexiou C
Anticancer Res; 2012 May; 32(5):1983-9. PubMed ID: 22593476
[TBL] [Abstract][Full Text] [Related]
8. Studies on the adsorption and desorption of mitoxantrone to lauric acid/albumin coated iron oxide nanoparticles.
Zaloga J; Feoktystov A; Garamus VM; Karawacka W; Ioffe A; Brückel T; Tietze R; Alexiou C; Lyer S
Colloids Surf B Biointerfaces; 2018 Jan; 161():18-26. PubMed ID: 29035747
[TBL] [Abstract][Full Text] [Related]
9. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases.
Lu B; Xiong SB; Yang H; Yin XD; Chao RB
Eur J Pharm Sci; 2006 May; 28(1-2):86-95. PubMed ID: 16472996
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution and targeting properties of iron oxide nanoparticles for treatments of cancer and iron anemia disease.
Alphandéry E
Nanotoxicology; 2019 Jun; 13(5):573-596. PubMed ID: 30938215
[TBL] [Abstract][Full Text] [Related]
11. MRI measurement of regional lung deposition in mice exposed nose-only to nebulized superparamagnetic iron oxide nanoparticles.
Martin AR; Thompson RB; Finlay WH
J Aerosol Med Pulm Drug Deliv; 2008 Dec; 21(4):335-42. PubMed ID: 18800881
[TBL] [Abstract][Full Text] [Related]
12. Effects of the isoflavonoid biochanin A on the transport of mitoxantrone in vitro and in vivo.
An G; Morris ME
Biopharm Drug Dispos; 2010 Jul; 31(5-6):340-50. PubMed ID: 20535833
[TBL] [Abstract][Full Text] [Related]
13. Iron oxide nanoparticles for sustained delivery of anticancer agents.
Jain TK; Morales MA; Sahoo SK; Leslie-Pelecky DL; Labhasetwar V
Mol Pharm; 2005; 2(3):194-205. PubMed ID: 15934780
[TBL] [Abstract][Full Text] [Related]
14. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.
Gokhale PC; Pei J; Zhang C; Ahmad I; Rahman A; Kasid U
Anticancer Res; 2001; 21(5):3313-21. PubMed ID: 11848489
[TBL] [Abstract][Full Text] [Related]
15. Particokinetics and extrapulmonary translocation of intratracheally instilled ferric oxide nanoparticles in rats and the potential health risk assessment.
Zhu MT; Feng WY; Wang Y; Wang B; Wang M; Ouyang H; Zhao YL; Chai ZF
Toxicol Sci; 2009 Feb; 107(2):342-51. PubMed ID: 19023088
[TBL] [Abstract][Full Text] [Related]
16. [Study on mitoxantrone albumin microspheres for liver targeting].
Zhang ZR; Qian WJ
Yao Xue Xue Bao; 1997; 32(1):72-8. PubMed ID: 11243225
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose.
Elford P; Bouchard J; Jaillet L; Pearson N; Rogue A; Sabadie C; Forster R
J Pharmacol Toxicol Methods; 2013; 68(3):374-83. PubMed ID: 23624021
[TBL] [Abstract][Full Text] [Related]
18. Effect of magnet implant on iron biodistribution of Fe@C nanoparticles in the mouse.
Escribano E; Fernández-Pacheco R; Valdivia JG; Ibarra MR; Marquina C; Queralt J
Arch Pharm Res; 2012 Jan; 35(1):93-100. PubMed ID: 22297747
[TBL] [Abstract][Full Text] [Related]
19. [Biodistribution of N-(2-hydroxypropyl) methacrylamide copolymer-bound mitoxantrone in mice bearing Ehrlich solid tumor].
Huang Y; Zhang Z; Liu W
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2004 Dec; 21(6):930-4. PubMed ID: 15646335
[TBL] [Abstract][Full Text] [Related]
20. [Studies on lung targeting gelatin microspheres of mitoxantrone].
Wang JH; Lu B; Xu PL; Bao DY; Zhang ZR
Yao Xue Xue Bao; 1995; 30(7):549-55. PubMed ID: 7484159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
